PT1748770E - Tratamento e prevenção de doença benigna da mama com 4-hidroxi-tamoxifeno - Google Patents

Tratamento e prevenção de doença benigna da mama com 4-hidroxi-tamoxifeno Download PDF

Info

Publication number
PT1748770E
PT1748770E PT05716433T PT05716433T PT1748770E PT 1748770 E PT1748770 E PT 1748770E PT 05716433 T PT05716433 T PT 05716433T PT 05716433 T PT05716433 T PT 05716433T PT 1748770 E PT1748770 E PT 1748770E
Authority
PT
Portugal
Prior art keywords
benign breast
hydroxy tamoxifen
breast disease
prevention
treatment
Prior art date
Application number
PT05716433T
Other languages
English (en)
Portuguese (pt)
Inventor
Elisabeth Le Nestour
Original Assignee
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04290761A external-priority patent/EP1579856A1/en
Priority claimed from US10/805,528 external-priority patent/US7507769B2/en
Application filed by Besins Int Lab filed Critical Besins Int Lab
Publication of PT1748770E publication Critical patent/PT1748770E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PT05716433T 2004-03-22 2005-03-10 Tratamento e prevenção de doença benigna da mama com 4-hidroxi-tamoxifeno PT1748770E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290761A EP1579856A1 (en) 2004-03-22 2004-03-22 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US10/805,528 US7507769B2 (en) 2004-03-22 2004-03-22 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
PT1748770E true PT1748770E (pt) 2008-07-16

Family

ID=34961912

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05716433T PT1748770E (pt) 2004-03-22 2005-03-10 Tratamento e prevenção de doença benigna da mama com 4-hidroxi-tamoxifeno

Country Status (16)

Country Link
EP (1) EP1748770B1 (https=)
JP (1) JP5072588B2 (https=)
CN (1) CN1946387B (https=)
AT (1) ATE391499T1 (https=)
AU (1) AU2005227072B2 (https=)
CA (1) CA2559748C (https=)
DE (1) DE602005005986T2 (https=)
DK (1) DK1748770T3 (https=)
ES (1) ES2306111T3 (https=)
MX (1) MXPA06010914A (https=)
NO (1) NO336767B1 (https=)
NZ (1) NZ549817A (https=)
PL (1) PL1748770T3 (https=)
PT (1) PT1748770E (https=)
RU (1) RU2357726C2 (https=)
WO (1) WO2005092309A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515041A1 (fr) * 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
DE69825495T2 (de) * 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
RU2188000C1 (ru) * 2001-09-27 2002-08-27 Нестерук Владимир Викторович Лекарственное средство на основе тамоксифена
PT1317921E (pt) * 2001-12-07 2009-11-06 Besins Mfg Belgium Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
WO2004054557A2 (en) * 2002-12-18 2004-07-01 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
JP4684655B2 (ja) * 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル 4−ヒドロキシタモキシフェンによる乳房密度低下
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
PL1694319T3 (pl) * 2003-12-15 2009-01-30 Besins Healthcare Lu Sarl Zastosowanie 4-hydroksytamoksyfenu do wytwarzania leku do leczenia ginekomastii

Also Published As

Publication number Publication date
NO20064609L (no) 2006-10-11
NZ549817A (en) 2010-06-25
ATE391499T1 (de) 2008-04-15
WO2005092309A1 (en) 2005-10-06
HK1096595A1 (en) 2007-06-08
CA2559748A1 (en) 2005-10-06
CA2559748C (en) 2013-05-28
CN1946387A (zh) 2007-04-11
EP1748770B1 (en) 2008-04-09
DK1748770T3 (da) 2008-08-04
EP1748770A1 (en) 2007-02-07
PL1748770T3 (pl) 2008-09-30
AU2005227072B2 (en) 2010-08-19
AU2005227072A1 (en) 2005-10-06
JP2007535505A (ja) 2007-12-06
NO336767B1 (no) 2015-10-26
RU2357726C2 (ru) 2009-06-10
MXPA06010914A (es) 2006-12-15
DE602005005986D1 (de) 2008-05-21
RU2006137280A (ru) 2008-04-27
ES2306111T3 (es) 2008-11-01
DE602005005986T2 (de) 2009-06-04
JP5072588B2 (ja) 2012-11-14
CN1946387B (zh) 2011-08-31

Similar Documents

Publication Publication Date Title
MXPA05010597A (es) Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.
Bocca Supraglottic laryngectomy and functional neck dissection
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
BR112022010806A2 (pt) Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama
MX2023012455A (es) Golexanolona para usarse en el tratamiento de la fatiga o deterioro cognitivo en pacientes con enfermedad hepatica.
EA201270298A1 (ru) Способ лечения злокачественной опухоли
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
PL1748770T3 (pl) Leczenie i zapobieganie dobrotliwej chorobie sutka 4-hydroksytamoksyfenem
NO20062904L (no) Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti
AR025718A1 (es) Metodo para reducir el riesgo de cancer
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
Jham et al. A case of maxillary sinus carcinoma
MD2849G2 (ro) Metodă de tratament al cancerului mamar la pacientele de vârstă înaintată
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
RU2008107113A (ru) Средство и способ профилактики и лечения пациентов с болезнью альцгеймера
RU2004116477A (ru) Применение n, n-диэтил-2-[4-(фенилметил)фенокси]этанамина моногидрохлорида (dppe) при лечении раковых заболеваний
CN208113994U (zh) 一种纯银排毒消炎女性内衣
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
CN204812059U (zh) 一种防辐射内裤
Scally et al. Uncontrolled Case Study of Medical Treatment for Elimination of Hypogonadism After Androgen Cessation in a Man With Human Immunodeficiency Virus Positivity and Secondary Polycythemia Related to Continuous Testosterone Treatment for 2 Years
Temelkova et al. Lipoma of the Neck. Open Access Maced J Med Sci. 2018 Oct 25; 6 (10): 1875-1877
García-Fernández et al. Predictive value of optical coherence tomography on the outcome of lung adenocarcinoma with choroidal metastases
Stehr et al. A Clinical Perspective of Bilateral Renal Tumors-Data from Three Consecutive German Cooperative Trials
Kim et al. Granular Cell Tumor in the Sartorius Muscle